Home > Business > Industry

Celltrion to cancel 1.7 trillion won in treasury shares to boost shareholder value

Published: 01 Apr. 2026, 11:38 Updated: 01 Apr. 2026, 14:29

The Celltrion logo [SCREEN CAPTURE]

Celltrion, a major Korean biopharmaceutical company, said Wednesday it will cancel 1.7 trillion won ($1.1 billion) worth of treasury shares this month as part of efforts to enhance shareholder value.

The company plans to cancel 9.1 million treasury shares, equivalent to about 4 percent of its outstanding shares, the company said in a press release.

The planned cancellation exceeds the combined 1.6 trillion won worth of treasury share cancellations carried out in 2024 and 2025.

"The company has decided to proceed with the scheduled large-scale share cancellation on April 13 to strengthen shareholder value amid growing uncertainty in the global economy," a company official said.

As for the 3.2 million treasury shares that will remain following the cancellation, Celltrion said it plans to use these shares strategically to support future growth, including mergers and acquisitions, development of new technologies and facility investments.

Yonhap